Bio-Path Inc. (BPTH)
0.82
-0.00 (-0.50%)
At close: Jan 28, 2025, 2:29 PM
undefined% (undefined)
| Bid | 0.8 |
| Market Cap | 4.73M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -8.34 |
| PE Ratio (ttm) | -0.1 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.84 |
| Volume | 51,154 |
| Avg. Volume (20D) | 2,205,128 |
| Open | 0.80 |
| Previous Close | 0.82 |
| Day's Range | 0.80 - 0.85 |
| 52-Week Range | 0.59 - 10.00 |
| Beta | undefined |
About BPTH
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials f...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 4, 2008
Employees 10
Stock Exchange NASDAQ
Ticker Symbol BPTH
Website https://www.biopathholdings.com
Analyst Forecast
According to 1 analyst ratings, the average rating for BPTH stock is "Buy." The 12-month stock price forecast is $20, which is an increase of 2339.02% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
1 month ago
+122.72%
Bio-Path Holdings shares are trading higher after ...
Unlock content with
Pro Subscription
3 months ago
+39.79%
Bio-Path shares are trading higher after the company announced it initiated a therapeutic program to develop BP1001-A for obesity and related metabolic diseases. This makes it the first application of DNAbilize technology for the development of a non-cancer application.
